Dapagliflozin associates with heart rate variability decline in T2DM patients on GLP-1 receptor agonist therapy: a prospective observational study.
A common diabetes drug combination may affect heart rhythm regulation, warranting clinical attention as these drugs are increasingly prescribed together.
This prospective observational study identifies an association between dapagliflozin use and heart rate variability decline in T2DM patients treated with GLP-1 receptor agonists, raising a clinically relevant autonomic nervous system interaction signal for this common combination therapy. While observational design prevents causal inference, the finding warrants attention as SGLT2 inhibitor + GLP-1 RA combinations become increasingly prevalent in T2DM management.
What the study was
- Study design
- Prospective observational study
- Population
- Type 2 diabetes mellitus patients on GLP-1 receptor agonist therapy receiving dapagliflozin
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Frontiers in Endocrinology
Why it surfaced
Clinically novel signal about HRV-SGLT2i interaction in combination therapy, though sample size unknown and observational design limits conclusions. Relevant to the growing GLP-1/SGLT2 combination therapy population.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.